Payment overview · 2025
General Payments
$150.72
6 reported records · 4 companies
Healthcare provider profile · identity verified
John A Hoehn, DO
Allopathic & Osteopathic Physicians|Family Medicine · SCHERERVILLE, IN · NPI 1891755690
Verified facts
What the public records show
CMS Open Payments records show John A Hoehn, DO received $150.72 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 45.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Ubrelvy, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.92 | 45.1% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $38.34 | 25.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.73 | 17.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.73 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.72 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.00 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.00 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $38.34 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 695 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 680 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 642 | 185 |
| Pantoprazole Sodium | Pantoprazole Sodium | 525 | 173 |
| Gabapentin | Gabapentin | 517 | 161 |
| Lisinopril | Lisinopril | 504 | 156 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 502 | 83 |
| Alprazolam | Alprazolam | 495 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 456 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 140 |
| Metformin Hcl | Metformin Hcl | 404 | 121 |
| Tizanidine Hcl | Tizanidine Hcl | 319 | 115 |
| Omeprazole | Omeprazole | 301 | 96 |
| Potassium Chloride | Potassium Chloride | 278 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 275 | 83 |
| Allopurinol | Allopurinol | 273 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 85 |
| Furosemide | Furosemide | 262 | 93 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 79 |
| Metformin Hcl Er | Metformin Hcl | 252 | 88 |
| Meloxicam | Meloxicam | 246 | 82 |
| Tramadol Hcl | Tramadol Hcl | 238 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 76 |
| Losartan Potassium | Losartan Potassium | 235 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 59 |
| Simvastatin | Simvastatin | 207 | 58 |
| Lorazepam | Lorazepam | 204 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 94 |
| Montelukast Sodium | Montelukast Sodium | 189 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 53 |
| Ozempic | Semaglutide | 158 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 49 |
| Famotidine | Famotidine | 137 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 131 | 104 |
| Bumetanide | Bumetanide | 122 | 44 |
| Carvedilol | Carvedilol | 121 | 43 |
| Cephalexin | Cephalexin | 121 | 82 |
| Synthroid | Levothyroxine Sodium | 118 | 33 |
| Glimepiride | Glimepiride | 117 | 34 |
| Methylprednisolone | Methylprednisolone | 116 | 96 |
| Trazodone Hcl | Trazodone Hcl | 111 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 38 |
| Ezetimibe | Ezetimibe | 101 | 31 |
| Sertraline Hcl | Sertraline Hcl | 98 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 28 |
| Celecoxib | Celecoxib | 94 | 33 |
| Nabumetone | Nabumetone | 91 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 82 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 11 |
| Finasteride | Finasteride | 79 | 29 |
| Spironolactone | Spironolactone | 79 | 27 |
| Prednisone | Prednisone | 76 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 23 |
| Warfarin Sodium | Warfarin Sodium | 76 | 24 |
| Baclofen | Baclofen | 75 | 18 |
| Lovastatin | Lovastatin | 74 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 74 | 20 |
| Pregabalin | Pregabalin | 74 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | 28 |
| Clonazepam | Clonazepam | 70 | 18 |
| Mirtazapine | Mirtazapine | 70 | 24 |
| Atenolol | Atenolol | 68 | 19 |
| Jardiance | Empagliflozin | 66 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 43 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 45 |
| Eliquis | Apixaban | 63 | 15 |
| Glipizide Er | Glipizide | 62 | 20 |
| Azithromycin | Azithromycin | 61 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Sucralfate | Sucralfate | 57 | 21 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 54 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Fluconazole | Fluconazole | 52 | 36 |
| Naproxen | Naproxen | 52 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 13 |
| Valsartan | Valsartan | 51 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 13 |
| Levofloxacin | Levofloxacin | 49 | 31 |
| Diazepam | Diazepam | 47 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 18 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 29 |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 13 |
| Estradiol | Estradiol | 35 | 15 |
| Temazepam | Temazepam | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 16 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Alendronate Sodium | Alendronate Sodium | 33 | 11 |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Lansoprazole | Lansoprazole | 32 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Telmisartan | Telmisartan | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 26 | 11 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Scopolamine | Scopolamine | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Linzess | Linaclotide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 11 |
| Glipizide | Glipizide | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Dexilant | Dexlansoprazole | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Alprazolam Xr | Alprazolam | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Climara | Estradiol | 11 | suppressed |
| Frovatriptan Succinate | Frovatriptan Succinate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.72 · 6 records | Novo Nordisk Inc | Auvelity, INSPIRE, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error